Exendin variant and conjugate thereof
AssigneePegbio Co., Ltd.
InventorsMichael M. Xu, Yongxiang Wang, Yinghui Zhang, Xiaosu Luo, Nian Gong, Lijie Zhang, Xiangjun Zhou
Life of this patent
Estimating the term…
Abstract
The invention provides a novel Exendin variant and the Exendin variant conjugate conjugating polymer thereon, the pharmaceutical composition comprising them and use of them for treating diseases such as reducing blood glucose, treating diabetes, especially Type II diabetes. The invention also provides the use of Exendin conjugate for lowering body weight.
Claims15
An Exendin variant conjugate having the activity of GLP-1 receptor agonist, wherein one or more polymer moieties are conjugated to cysteine residue of the Exendin variant, wherein the one or more polymer moieties have a molecular weight of from 21 kDa to 29 kDa, and wherein the one or more polymer moieties are each independently polyethylene glycol.
Dependencies are inferred from the claim text.